NBDC Research ID: hum0292.v1
SUMMARY
Aims: To develop predictive biomarkers for the treatment of castration-resistant prostate cancer (CRPC) such as abiraterone, enzalutamide, docetaxel, and cabazitaxel based on genomic analyses of cell-free DNA (cfDNA) and circulating tumor cells (CTC).
Methods: One hundred CRPC patients eligible for treatment with either abiraterone or enzalutamide were prospectively enrolled at 17 institutions in Japan. cfDNA and paired lymphocyte DNA per patient were used for sequencing library preparation, and unique molecular identifiers were added. Targeted sequencing was performed using Illumina NovaSeq (Our custom gene panel captures the exonic regions of 88 genes).
Participants/Materials: 100 CRPC patients eligible for abiraterone or enzalutamide
| Dataset ID | Type of Data | Criteria | Release Date |
|---|---|---|---|
| JGAS000330 | NGS (Target Capture) | Controlled-access (Type I) | 2021/09/24 |
*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more
| Participants/Materials | CRPC patients eligible for abiraterone or enzalutamide (ICD10: C61): 100 cases |
| Targets | Target Capture |
| Target Loci for Capture Methods | 88 genes |
| Platform | Illumina [NovaSeq 6000] |
| Library Source | cfDNA and paired lymphocyte DNA extracted from peripheral blood |
| Cell Lines | - |
| Library Construction (kit name) | ThruPLEX tag-seq, KAPA HyperChoice Probes |
| Fragmentation Methods | Ultrasonic fragmentation (Covaris) |
| Spot Type | Paired-end |
| Read Length (without Barcodes, Adaptors, Primers, and Linkers) | 150 bp |
| Japanese Genotype-phenotype Archive Dataset ID | JGAD000441 |
| Total Data Volume | 1.8 TB (fastq) |
| Comments (Policies) | NBDC policy |
DATA PROVIDER
Principal Investigator: Shusuke Akamatsu
Affiliation: Department of Urology, Graduate School of Medicine, Kyoto University
Project / Group Name: -
Funds / Grants (Research Project Number):
| Name | Title | Project Number |
|---|---|---|
| KAKENHI Grant-in-Aid for Scientific Research (B) | Understanding the biological mechanisms of defective DNA damage repair in prostate cancer using cell-free DNA analysis | 20H03814 |
| AstraZeneca Externally Sponsored Scientific Research | The prevalence of germline and somatic DNA repair gene mutations in Japanese prostate cancer patients | ESR I: NCR-17-13159 |
| Astellas Research Grant | Identification of factors predicting response to enzalutamide using tissues of castration-resistant prostate cancer | - |
PUBLICATIONS
| Title | DOI | Dataset ID | |
|---|---|---|---|
| 1 | Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer | doi: 10.1158/1078-0432.CCR-21-2328 | JGAD000441 |
| 2 |
USRES (Controlled-access Data)
| Principal Investigator | Affiliation | Country/Region | Research Title | Data in Use (Dataset ID) | Period of Data Use |
|---|---|---|---|---|---|
